Observations placeholder

Ustekinumab ( proprietary commercial name Stelara, Centocor) is a human monoclonal antibody. It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.Ustekinumab is approved in Canada, Europe and the United States to treat moderate to severe plaque psoriasis.

It has been tested in Phase II studies for multiple sclerosis and sarcoidosis.  On September 24, 2013, the FDA approved the use of ustekinumab for the treatment of psoriatic arthritis.

"You should not use this medicine if you have received a BCG (Bacillus Calmette and Guérin) vaccine within the past 12 months.  Serious infections may occur during treatment with ustekinumab. Call your doctor right away if you have signs of infection such as: fever, chills, muscle pain, shortness of breath, weight loss, diarrhea or stomach pain, burning when you urinate, feeling very tired, skin warmth or redness, painful skin sores, or coughing up blood."

On Sep, 12, 2015: 3,771 people reported to have side effects when taking Stelara. Among them, 54 people (1.43%) have Death.

Time on Stelara when people have Death * :

Gender of people who have Death when taking Stelara * :

Age of people who have Death when taking Stelara * :

Top conditions involved for these people * :

1. Psoriasis (54 people, 100.00%)
2. Gastric ulcer (23 people, 42.59%)
3. Hypertension (3 people, 5.56%)
4. Infection (2 people, 3.70%)
5. Nasopharyngitis (2 people, 3.70%)